1. Variants and vaccines impact nasal immunity over three waves of SARS-CoV-2.
- Author
-
Walsh JML, Miao VN, Owings AH, Tang Y, Bromley JD, Kazer SW, Kimler K, Asare C, Ziegler CGK, Ibrahim S, Jivanjee T, George M, Navia AW, Drake RS, Parker A, Billingsley BC, Dotherow P, Tarugu S, Kota SK, Laird H, Wichman TG, Davis YT, Dhaliwal NS, Pride Y, Guo Y, Senitko M, Harvey J, Bates JT, Diamond G, Garrett MR, Robinson DA, Frame IJ, Lyons JJ, Robinson TO, Shalek AK, Horwitz BH, Glover SC, and Ordovas-Montanes J
- Subjects
- Humans, Adult, Male, Vaccination, Middle Aged, Female, Single-Cell Analysis, Immunity, Mucosal, RNA, Viral immunology, Aged, SARS-CoV-2 immunology, COVID-19 immunology, COVID-19 virology, Nasal Mucosa immunology, Nasal Mucosa virology, COVID-19 Vaccines immunology
- Abstract
Viral variant and host vaccination status impact infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), yet how these factors shift cellular responses in the human nasal mucosa remains uncharacterized. We performed single-cell RNA sequencing (scRNA-seq) on nasopharyngeal swabs from vaccinated and unvaccinated adults with acute Delta and Omicron SARS-CoV-2 infections and integrated with data from acute infections with ancestral SARS-CoV-2. Patients with Delta and Omicron exhibited greater similarity in nasal cell composition driven by myeloid, T cell and SARS-CoV-2
hi cell subsets, which was distinct from that of ancestral cases. Delta-infected samples had a marked increase in viral RNA, and a subset of PER2+ EGR1+ GDF15+ epithelial cells was enriched in SARS-CoV-2 RNA+ cells in all variants. Prior vaccination was associated with increased frequency and activation of nasal macrophages. Expression of interferon-stimulated genes negatively correlated with coronavirus disease 2019 (COVID-19) severity in patients with ancestral and Delta but not Omicron variants. Our study defines nasal cell responses and signatures of disease severity across SARS-CoV-2 variants and vaccination., Competing Interests: Competing interests: V.N.M. reports compensation from MPM Capital and RA Capital Management unrelated to this work. S.W.K. reports compensation for consulting services with Monopteros Therapeutics, Flagship Pioneering and Radera Biosciences. M.S. reports compensation for consulting services with GE Precision Healthcare. J.J.L. reports compensation for consulting services with Blueprint Medicines and Human Immunology Biosciences. J.O.-M. reports compensation for consulting services with Cellarity, Tessel Biosciences and Radera Biotherapeutics. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Hovione, Ochre Bio, Third Rock Ventures, Relation Therapeutics, Dahlia Biosciences, Bio-Rad Laboratories, IntrECate Biotherapeutics, FogPharma and Passkey Therapeutics. C.G.K.Z., V.N.M., A.H.O., A.W.N., Y.T., J.D.B., A.K.S., S.C.G., B.H.H. and J.O.-M. are co-inventors on a provisional patent application relating to methods of stratifying and treating viral infections. The other authors declare no competing interests., (© 2025. Springer Nature America, Inc.)- Published
- 2025
- Full Text
- View/download PDF